Agios Patent-Cliff Exposure & CMS Drug Spending Portfolio

Agios (US): 1 reconciled FDA prescription therapies, $12.7M 2024 CMS Part D & Medicaid spend, and $32,610 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2041-01-01
2024 CMS Total Public Spend$12.7M
2024 Medicare Part D Spend$6.0M
2024 Medicaid Spend$6.7M
California HCAI SB 17 FilingsSpecialty launch notice ($32,610 intro WAC)